Recombinant human IgG1 Fc Protein, Tag free, 200µg

Background
Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). IgG1 Fc was reported has a novel role as a potential anti-inflammatory drug for treatment of human autoimmune diseases.(1)

Source
Recombinant Human IgG Fc, Tag Free (FCC-H5214) is expressed from human 293 cells (HEK293). It contains AA Glu 99 - Lys 330 (Accession # P01857-1).
Predicted N-terminus: Glu 99

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 26.1 kDa. The protein migrates as 32-34 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "TNX-1500, an Fc-modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Renal Allograft Survival"
Lassiter, Otsuka, Hirose et al
Am J Transplant (2023)
(2) "Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis"
Sivadasan, Bril
Immunotherapy (2023)
(3) "Generation and characterization of QLS22001, a humanized monoclonal antibody that neutralizes IL-17A and IL-17F with an extended half-life"
Ma, Zhang, Liu et al
Int Immunopharmacol (2023) 117, 109947
Showing 1-3 of 11533 papers.

Citations

Site-Specific Crosslinking of Antibodies
Authors: B Agnew, et al
Journal: US20190177438A1 43629
Application: Fluorescent labeled

Compositions and methods for inhibiting WNT signaling
Authors: M Dong, et al
Journal: 20190031734A1 43496
Application: BLI

Impact of payload hydrophobicity on stability of antibody-drug-conjugates
Authors: Buecheler JW, et al.
Journal: Mol Pharm 2018
Application: BLI

Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery
Authors: Li Zhou, et al.
Journal: Biomaterials 2016
Application: As a control in Cell-based assay

Frizzled proteins are colonic epithelial receptors for C. difficile toxin B
Authors: Tao L, et al.
Journal: Nature 2016
Application: As a control in BLI assay

Multifunctional RNA nanoparticles
Authors: Kirill A. Afonin, et al.
Journal: Nano Lett 2014
Application: As a control in Cell-based assay